Company Overview and News

 
Broker's Call: Time Technoplast (Buy)

2018-10-16 thehindubusinessline
Time Technoplast is engaged in manufacturing plastics products. The company’s segments include polymer products and composite products. It offers industrial packaging products, infrastructure products, technical products, material handling products and composite cylinders. The company’s rigid industrial packaging products include high molecular high density polyethylene (HM-HDPE) drums, jerry-cans, pails and intermediate bulk containers.
SOUTHBANK 532218 532856 TIMETECHNO

1
An evening walk down Dalal Street | Sensex jumps 297 pts amid stable rupee and oil prices

2018-10-16 moneycontrol
Bulls kept the momentum going on Dalal Street for third consecutive session on Tuesday as the Sensex gained nearly 300 points and all sectoral indices ended in the green despite mixed global cues. Stable rupee and crude oil prices, and healthy start to September quarter earnings season aided the rally.
BHRYY 500325 500469 500228 RELIANCE TCHQY FEDA 532218 532755 532215 535789 505200 SOUTHBANK 532187 AXISBANK 534816 RIGD FEDS HDFCBANK INFRATEL FEDERALBNK EICHERMOT RLNIY ECQRY AXB INDUSINDBK IBN IDKQY FDBAY JSWSTEEL TECHM AXBKY IBULHSGFIN AXBA ICICIBANK HDB 532174 500180

 
European shares rebound from 22-month low

2018-10-16 thehindubusinessline
European shares rose on Tuesday helped by stronger defensive stocks as the focus turned to the start of the reporting season which is expected to deliver double-digit earnings growth for the third quarter.
BAESY SOUTHBANK 532218 BA DTEGF BAESF DTEGY

 
NIIF’s Fund of Funds invests Rs 660 cr in H-CARE 2

2018-10-16 thehindubusinessline
NIIF’s Fund of Funds has invested Rs 660 crore in HDFC’s real estate investment platform HDFC Capital Affordable Real Estate – 2 (H-CARE 2). The investment is done along with a wholly-owned subsidiary of one of NIIF’s shareholders - the Abu Dhabi Investment Authority (ADIA). This is the second investment from National Investment and Infrastructure Fund since its inception.
AXBKY SOUTHBANK AXBA ICICIBANK AXB AXISBANK 532174 IBN 532218 532215

 
South Indian Bank jumps 16% after Q2 results as PAT increases 16-fold

2018-10-16 moneycontrol
South Indian Bank shares rallied as much as 16 percent in morning trade on October 16 after the private lender reported over a 16-fold rise in profit for the quarter ended September 30.
SOUTHBANK 532218

 
Zee Media rallies 17% on Q2 results

2018-10-16 thehindubusinessline
Shares of Zee Media Corp Ltd jumped as much as nearly 17 per cent to Rs 29.90, in their biggest intraday percentage gain in over three weeks.
SOUTHBANK 532218

 
Future Retail stocks spurt nearly 5%

2018-10-16 thehindubusinessline
The potential cash-and-stock deal, which is in its final stages, could be worth Rs 2,500 crore ($338 million) and is likely to be signed in the next two weeks. - Bloomberg
SOUTHBANK 570002 FRLDVR FRL 523574 532218

 
Hathway, DEN Networks rally 8% as RIL eyes controlling stake

2018-10-16 thehindubusinessline
Shares of cable TV and broadband service providers Hathway Cable & Datacom and DEN Networks Ltd jumped 8.16 per cent and 7.82 per cent, respectively.
DEN SOUTHBANK 500325 RELIANCE RIGD 532218 533137 RLNIY

 
Indiabulls Housing shares jump 3%

2018-10-16 thehindubusinessline
Share of Indiabulls Housing Finance jumped as much as 3 per cent to Rs 976.80 as the mortgage lender had on Mondday posted 21.5 per cent rise in September quarter profit of Rs 1,044 crore ($141.28 million).
SOUTHBANK 535789 IBULHSGFIN IDKQY 532218

 
South Indian Bank shares jump to 3-year high

2018-10-16 thehindubusinessline
Shares of South Indian Bank rallied as much as 16.7 per cent to Rs 14.7, in their biggest intraday percentage gain in over three years as the September-quarter profit surged to Rs 70.13 crore ($9.49 million) from Rs 4.32 crore a year earlier.
SOUTHBANK 532218

 
The South Indian Bank Limited - Investor Presentation

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOUTHBANK 532218

 
The South Indian Bank Limited - Outcome of Board Meeting

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOUTHBANK 532218

 
The South Indian Bank Limited - Financial Result Updates

2018-10-15 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
SOUTHBANK 532218

 
Kotak Life Managing Director G Murlidhar: We are very balanced company by design

2018-10-15 freepressjournal.in
Kotak Mahindra Life Insurance Company (Kotak Life) was founded in 2001 as a 74:26 joint venture between Kotak Mahindra Group and Old Mutual. The bank acquired Old Mutual’s 26 per cent stake in October 2017, making the insurance entity a 100 per cent subsidiary of Kotak Mahindra Bank. The acquisition further cemented massive growth expectations from the life insurance business. G Murlidhar, Kotak Life’s Managing Director, throws light on the performance of the company and the life insurance industry in an interview with Free Press Journal’s S Narayanan.
SOUTHBANK KMBKY KOTAKBANK OML 532218 500247

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...